AnaptysBio Total Liabilities 2014-2025 | ANAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AnaptysBio total liabilities from 2014 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AnaptysBio total liabilities from 2014 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.4B
Amgen (AMGN)	$163.2B
Gilead Sciences (GILD)	$142.1B
Vertex Pharmaceuticals (VRTX)	$120.3B
Bristol Myers Squibb (BMY)	$95.4B
CSL (CSLLY)	$86B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$43.1B
Argenex SE (ARGX)	$36.6B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21B
Insmed (INSM)	$19.9B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$17.2B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.5B
Moderna (MRNA)	$12.6B
QIAGEN (QGEN)	$11.4B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9.1B
Exact Sciences (EXAS)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.5B